Clinical

Articles

Though previous reports have suggested that an EGFR tyrosine kinase inhibitor plus an anti-VEGF agent might offer benefit to patients with brain metastasis or pleural effusion, the study authors could not identify its advantage.

Osimertinib Plus Bevacizumab Did Not Prolong PFS in Patients With EGFR T790M–Mutated NSCLC

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLC

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.

FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLC

Full approval has been granted by the FDA to osimertinib (Tagrisso) for use as adjuvant therapy following tumor resection among patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

FDA Approves Osimertinib as Adjuvant Therapy Following Resection of NSCLC with EGFR Mutations

Janssen submitted a biologics license application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

Janssen Submits BLA for Amivantamab to Treat Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Though researchers found that Black patients with early-stage non-small cell lung cancer are now more likely to receive the most effective treatment compared to a decade ago, the disparity for this patient population persists.

Study Finds Racial Disparities in ES-NSCLC Persist Despite Gains in Treatment

Adagrasib demonstrated an acceptable safety profile and promising clinical activity in pretreated patients with non-small cell lung cancer, colorectal cancer, and other solid tumors with a KRAS G12C mutation.

Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors

An interim analysis of the trial revealed that among patients with previously untreated advanced ALK-positive non-small cell lung cancer, those who received lorlatinib (Lorbrena) had significantly longer PFS, a higher overall and intracranial response, and better quality of life.

Phase 3 CROWN Trial Shows Promise for Lorlatinib in Previously Untreated ALK-Positive NSCLC

These study results suggest that osimertinib as adjuvant therapy is an effective treatment strategy for patients with stage IB to IIIA EGFR-positive non-small cell lung cancer following complete tumor resection.

Osimertinib Extends Disease-Free Survival in Resected EGFR-Mutated NSCLC in Phase 3 ADAURA Trial 

The FDA approved a 1500 mg fixed dose of durvalumab (Imfinzi) administered every 4 weeks for the treatment of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.

Non-Small Cell Lung Cancer (NSCLC) | Topics